Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | PRKCA | P17252 | 1/20 | 0.31 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.31 |
| ▸ | RASGRP3 | Q8IV61 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22254481 | 0.89 | TDP1 (0.30) | TDP1 | |
| SCHEMBL22253607 | 0.82 | CHRNB2 (0.34) | TDP1KMT2AMAPK1HIF1ASLC6A2 | |
| SCHEMBL21930213 | 0.80 | SIGMAR1 (0.42) | TDP1KMT2AMAPK1ALDH1A1L3MBTL1 | |
| SCHEMBL21930565 | 0.80 | SIGMAR1 (0.42) | TDP1KMT2AMAPK1ALDH1A1L3MBTL1 | |
| SCHEMBL26731620 | 0.74 | SIGMAR1 (0.41) | TDP1KMT2AALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL22253652 | 0.70 | LMNA (0.34) | TDP1KMT2AALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL17542332 | 0.69 | KDM1A (0.37) | TDP1GAAPRKCAPRKCERASGRP3 | |
| SCHEMBL26194440 | 0.69 | SMN1; SMN2 (0.39) | TDP1KMT2AALDH1A1KDM4EGAA | |
| SCHEMBL17542330 | 0.69 | KDM1A (0.37) | TDP1GAAPRKCAPRKCERASGRP3 | |
| SCHEMBL23109724 | 0.68 | EED (0.34) | HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3781574-B1 | MACROCYCLIC SPIROETHERS AS MCL-1 INHIBITORS | ASCENTAGE PHARMA SUZHOU CO LTD (CN) | 2023-05-10 | — | — | EP | disclosed |
| EP-3781574-B1 | MACROCYCLIC SPIROETHERS AS MCL-1 INHIBITORS | ASCENTAGE PHARMA SUZHOU CO LTD (CN) | 2023-05-10 | — | — | EP | disclosed |
| US-11498928-B2 | Macrocyclic spiroethers as Mcl-1 inhibitors | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2022-11-15 | — | — | US | disclosed |
| US-20210340158-A1 | MACROCYCLIC SPIROETHERS AS MCL-1 INHIBITORS | ASCENTAGE PHARMA GROUP CORP LIMITED (CN) | 2021-11-04 | — | — | US | disclosed |
| US-20210340158-A1 | MACROCYCLIC SPIROETHERS AS MCL-1 INHIBITORS | ASCENTAGE PHARMA GROUP CORP LIMITED (CN) | 2021-11-04 | — | — | US | disclosed |
| CN-112867722-A | MACROCYCLIC SPIROETHERS (MACROCYCLIC SPIROETHERS) as MCL-1 inhibitors | 苏州亚盛药业有限公司 | 2021-05-28 | — | — | CN | disclosed |
| WO-2020147802-A1 | MACROCYCLIC SPIROETHERS AS MCL-1 INHIBITORS | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2020-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11498928-B2 | Macrocyclic spiroethers as Mcl-1 inhibitors | MCL1, BCL9, BCL9L | TDP1 3388/4885KMT2A 891/4885MAPK1 1235/4885 |
| US-20210340158-A1 | MACROCYCLIC SPIROETHERS AS MCL-1 INHIBITORS | MCL1, BCL9, BCL9L | TDP1 3388/4885KMT2A 891/4885MAPK1 1235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.